亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。

Therapeutic Hydrogels of Nonsteroidal Anti-Inflammatory Drugs

總結
· Oligopeptidescomprising D-amino acids to replace L-amino, produce protease resistant motifs
技術優勢
Bio stableand biocompatible supramolecular hydrogels of D-peptides and therapeutic smallmolecules increase target selectivity and decrease adverse drug reactionsTheinvention confers proteolytic resistance and preserves drug activity forsustained releaseAdministered as topical gels or creams to use for relieving pain induced bylocal inflammationThetherapeutic hydrogels serve as a cheap, safe, and effective carrier for drug toreduce ADRsThesynthetic route for said peptidic conjugate is facile, well established, andeasy to scale up
詳細技術說明
Therapeutic Hydrogels of Nonsteroidal Anti-Inflammatory Drugs:D-peptides/NSAIDs conjugates boost drugselectivity and reduce side effects
*Abstract

Background:  

Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely andsystematically used in high doses for the treatment of acute or chronic painsand inflammations. NSAIDs effectively relieve pain and treat inflammation bybinding to the cyclooxygenase-2 (COX-2) enzyme. However, NSAIDs also inhibitCOX-1, which causes adverse drug effects (ADRs) such as: gastrointestinal ulceration,stomach bleeding, renal failure, and cardiovascular risks. ADRs not only limitthe use of otherwise effective drugs, but also lead to the attrition of newdrugs in clinical trials.

Until now, nosimple and general approach for reducing “off-target” effects of NSAIDs hasexisted. This invention employs novel multifunctional supramolecularhydrogelators made of unnatural amino acids or peptides (D-amino acids orD-peptides) and an NSAID as a new approach for delivering therapeutic agents bybiostable, target specific, and potent hydrogels. These therapeutic hydrogelsare stable scaffolds for long-term drug release and significantly reduce ADRs,boosting the selectivity for COX-2 over COX-1 by more than 20 times. Thesecompounds may be functionalized with other active agents, such as anticancertherapeutic agents, anti-HIV drugs or imaging agents, therefore fulfillingmultiple biomedicinal roles.


*IP Issue Date
None
*IP Type
Utility
國家
United States
申請號碼
14/441,773
國家/地區
美國

欲了解更多信息,請點擊 這裡
移動設備